APL-045 / Apollo Therap - LARVOL DELTA

Preclinical development of APL-045: A selective PERK inhibitor targeting ER stress pathways in cancer (AACR 2025) - "These properties have translated to high bioavailability. This favourable profile is projected to represent a best-in-class PERK inhibitor.These data describe the efficacy and drug-like properties of APL-045, a candidate stage, best-in-class PERK inhibitor poised to progress into IND-enabling and clinical studies."

Preclinical • Colorectal Cancer • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • ATF4